相关实验视频
Updated: May 3, 2026

13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.0K
在早产婴儿的血清胆红素总动态的基于模型的表征
Meng Chen1, Alain Beuchée2, Emmanuelle Levine1
1University of Rennes, Rennes University Hospital, LTSI-INSERM U1099, F-35000, Rennes, France.
Pediatric research
|November 7, 2024
概括
这项研究模拟了早产婴儿的血清 bilirubin (TSB) 总衰减,为监测和预测NICU中的临床事件提供了一个新的工具. 患者特异型模型为TSB动态提供了长期的洞察力,超出了出生后的最初几个小时.
科学领域:
- 新生儿医学 新生儿医学
- 生物数学是生物数学.
- 临床信息学 临床信息学
背景情况:
- 过早出生的婴儿在全血清胆红素 (TSB) 代谢中遇到独特的挑战.
- 现有的模型往往侧重于出生后的最初几个小时,在了解长期TSB动态方面留下了一个差距.
- 早期检测TSB相关的发病率对于改善早产新生儿的结果至关重要.
研究的目的:
- 开发和验证一种数学模型,描述早产婴儿中TSB与年龄相关的自然动态.
- 探索患者特异型模型参数作为预测新生儿发病率的生物标志物的实用性.
- 为TSB衰变提供长期的视角,超越典型的72-96小时观察期.
主要方法:
- 一个指数式衰变模型被提出并应用于个别的早产婴儿.
- 通过最小化测量TSB值和模型预测之间的误差来得出患者特定的参数.
- 模型性能使用根平均平方误差 (RMSE) 进行评估,并分析其与高风险临床事件的相关性.
主要成果:
- 患者特定的指数衰变模型成功地适用于72名早产婴儿 (怀孕24至32周).
- 模型适配的中位数根-平方平均误差 (RMSE) 为8.74 [4.89,14.25] μmol/L,表明TSB动态的有效表征.
- 该模型在估计临床事件的发生方面表现出潜力,例如死性肠球炎,正如受影响的婴儿中较高的RMSE值所表明的那样.
结论:
- 开发的数学模型提供了对早产婴儿长期TSB衰变的可靠描述.
- 模型参数和拟合错误提供了有价值的见解,并可作为预测新生儿发病率的生物标志物.
- 这种方法为开发基于模型的临床决策支持系统铺平了道路,以优化NICU监测和早期发现关键事件.
相关概念视频
Measurement of Bioavailability: Pharmacodynamic Methods
1.0K
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Jaundice
35
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
35

